Virtual Library
Start Your Search
Y. Nagata
Author of
-
+
P2.05 - Poster Session with Presenters Present (ID 463)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Radiotherapy
- Presentations: 2
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.05-024 - Current Status of Stereotactic Body Radiation Therapy (SBRT) in Japan (ID 6387)
14:30 - 14:30 | Author(s): Y. Nagata
- Abstract
Background:
Stereotactic body radiotherapy (SBRT) is a technique, introduced in the late 1990s. SBRT is a method of using single 10-20Gy of high dose and hypofractionated radiotherapy. Recently, many papers have been published on its clinical results, especially in early stage lung cancer.
Methods:
To recognize the current status of SBRT in Japan, a nation-wide survey was conducted by the Japan Conformal External Beam Radiotherapy Group (J-CERG).
Results:
The questionaire was sent to 227 institutions. One-hundred and forty-nine institutions responded by the end of May 2015.The fixing apparatus, respiratory regulation, treatment planning and verification was surveyed. For regulation of respiratory movement, abdominal wall compression, breath-holding, respiratory gating and tumor chasing methods were used. For irradiation technique, 6 to 10 non-coplanar beams or multiple arc beams were mainly adopted.
Conclusion:
The current status of SBRT in Japan was recognized.
-
+
P2.05-050 - Impact of Inflammation and Sarcopenia on Outcomes after Stereotactic Body Radiotherapy for T1N0M0 Non-Small Cell Lung Cancer (ID 4059)
14:30 - 14:30 | Author(s): Y. Nagata
- Abstract
Background:
The purpose was to evaluate impact of systemic inflammation and sarcopenia on outcomes after stereotactic body radiotherapy (SBRT) for T1N0M0 non-small cell lung cancer (NSCLC) as a supplementary analysis of Japan Clinical Oncology Group (JCOG) study JCOG0403.
Methods:
Pretreatment serum C-reactive protein (CRP) was used as a marker for systemic inflammation. Patients were divided into high and low CRP groups with a threshold value of 0.3 mg/dL. Paraspinous musculature area (PMA) at a level of the 12th thoracic vertebra was measured on simulation CT with thresholding Hounsfield Units between -29 and 150. When PMA was lower than the gender-specific median, the patient was classified as sarcopenia. Toxicities, overall survival (OS) and cumulative incidence of cause-specific death were compared between groups. Kaplan-Meier method and cumulative incidence function were applied to estimate proportion of OS and cumulative incidence of cause-specific death, respectively.
Results:
Of 169 patients enrolled into JCOG0403, 60 operable and 92 inoperable patients were included into this study after excluding 5 patients ineligible for JCOG0403 and 12 patients whose simulation CT images were unavailable or unsuitable for the PMA measurement. Forty-two patients were classified as high CRP. Medians of PMA were 31.6 cm[2] (range, 12.6-52.9) and 25.1 cm[2] (range, 3.4-38.5) in male and female, respectively. Proportions of toxicities Grade 3-4 were 19.1% and 10.9% in the high and low CRP groups; and 17.1% and 9.2% in the sarcopenia and non-sarcopenia groups, respectively. In the operable patient cohort, OS significantly differed between the CRP groups (log-rank test P=0.009; hazard ratio of high CRP 2.43, 95% confidence interval 1.23-4.80; 3-year OS of 58.8% and 83.6% for high and low CRP, respectively). This difference in OS was mainly contributed by difference in lung cancer death (Gray’s test P=0.070; 3-year cumulative incidence of 29.4% and 7.1%, respectively). No impact of sarcopenia on OS was observed in operable patients. In the inoperable patient cohort, OS did not differ between the CRP groups (log-rank test P = 0.925). No significant difference was observed in OS between the sarcopenia groups, either.
Conclusion:
The present study suggests that systemic inflammation may provide prognostic information for operable patients receiving SBRT for early-stage NSCLC. Further studies are warranted to confirm these findings.
